35
Participants
Start Date
October 31, 2012
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
X-82 oral
X-82 oral for 24 weeks or until unacceptable toxicity develops
ranibizumab (Lucentis)
Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
Elman Retina Group, Baltimore
Retina Consultants of Houston, Houston
Retina Research Institute of Texas, Abilene
Retina Vitreous Associates Medical Group, Beverly Hills
New England Retina Associates, New London
Lead Sponsor
Tyrogenex
INDUSTRY